

## 2024 to 2025 RSV season

The respiratory syncytial virus (RSV) season in Georgia will start on October 1, 2024, and run through March 3, 2025. Qualifying infants born during RSV season will need fewer than five doses for protection until the season ends. If the season extends into March, dosing exceptions from March 3, 2024, through March 31, 2024, will be allowed for high-risk infants discharged from the hospital in both February and March who do not receive the March dose in the hospital. We will continuously monitor the start and end of the RSV season, especially considering the recent atypical RSV levels observed in Georgia. Based on RSV surveillance data reported by the Centers for Disease Control and Prevention (CDC) and the Georgia Department of Public Health (GDPH), Amerigroup Community Care may continue to approve Synagis (palivizumab) doses on a monthly basis for eligible patients until RSV levels are below threshold.

Effective October 1, 2024, the Synagis criteria have been updated to include additional criteria limiting the use of Synagis to when Beyfortus (nirsevimab) has not been given and is not accessible as stated below:

- Individual has not received Beyfortus (nirsevimab) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease for this RSV season; **and**
- Individual does not have access to Beyfortus (nirsevimab) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease

To view the full criteria, please go to the [searchable formulary](#) or you may call the Prior Authorization Call Center to request a copy of the Medicaid criteria for Georgia at **800-454-3730**.



**Email is the quickest and most direct way to receive important information from us.**

To start receiving email from us (including some sent in lieu of fax or mail), submit your information using the QR code to the right or via our online form: <https://bit.ly/signup-agp-ga>.